636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Autor: | Kong, B.Y., Lin, F.P-Y., Espinoza, D., Thavaneswaran, S., Meniawy, T., Desai, J., Harrup, R., Selva-Nayagam, S., Charakidis, M., Cuff, K., Sebastian, L., Lee, C.K., Chinchen, S., Thomas, D.M., Ballinger, M.L., Simes, J., Goldstein, D. |
---|---|
Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S505-S505 |
Databáze: | ScienceDirect |
Externí odkaz: |